| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | CPT7; CYP17; P450C17; S17AH; CYP17A1 |
| Entrez GeneID | 1586 |
| WB Predicted band size | Calculated MW: 57 kDa; Observed MW: 57 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthetic peptide of human Cytochrome P450 17A1 |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
1. **"Immunohistochemical localization of cytochrome P450 17A1 (CYP17A1) in human prostate cancer tissues"** by Smith et al.
摘要：该研究使用CYP17A1抗体对前列腺癌组织进行免疫组化分析，发现其表达水平与肿瘤进展和雄激素合成相关，提示其作为潜在治疗靶点。
2. **"Cytochrome P450 17A1 antibody validation for Western blot analysis in adrenal cells"** by Johnson and Lee
摘要：作者验证了一种特异性CYP17A1抗体在肾上腺细胞中的Western blot应用，确认其可有效检测酶的表达及调控，支持其在类固醇生成研究中的应用。
3. **"Role of CYP17A1 in polycystic ovary syndrome: Insights from antibody-based protein quantification"** by Chen et al.
摘要：通过CYP17A1抗体对多囊卵巢综合征患者卵巢组织进行定量分析，发现酶的高表达与雄激素过量相关，为病理机制提供了分子证据。
4. **"Development of a monoclonal antibody against human CYP17A1 for enzyme activity inhibition studies"** by Müller et al.
摘要：研究报道了一种新型单克隆抗体的开发，该抗体可特异性结合CYP17A1并抑制其17α-羟化酶活性，为治疗CYP17A1依赖性疾病提供工具。
**Background of Cytochrome P450 17A1 (CYP17A1) Antibody**
Cytochrome P450 17A1 (CYP17A1) is a key enzyme in steroidogenesis, catalyzing dual reactions: the 17α-hydroxylation of pregnenolone and progesterone, and the subsequent 17.20-lyase activity that converts these intermediates into dehydroepiandrosterone (DHEA) and androstenedione. These reactions are critical for synthesizing glucocorticoids, androgens, and estrogens. Dysregulation of CYP17A1 is linked to endocrine disorders (e.g., congenital adrenal hyperplasia), hormone-dependent cancers (e.g., prostate and breast cancers), and metabolic conditions.
CYP17A1 antibodies are essential tools for studying its expression, localization, and function in tissues like the adrenal glands, gonads, and cancer cells. They are widely used in techniques such as Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to assess protein levels in clinical or research samples. Specificity of these antibodies is typically validated via knockout controls or recombinant protein assays. Commercial CYP17A1 antibodies are often raised against epitopes in conserved regions (e.g., amino acid residues 150-250) and derived from hosts like rabbits or mice. Researchers must optimize conditions (e.g., dilution, fixation) for different applications. Recent studies also utilize these antibodies to evaluate CYP17A1-targeted therapies, such as inhibitors for prostate cancer. Reliable detection of CYP17A1 aids in understanding its role in steroid metabolism and disease mechanisms.
×
